|
Originally published In Press as doi:10.1074/jbc.M202130200 on October 9, 2002
J. Biol. Chem., Vol. 277, Issue 50, 48427-48433, December 13, 2002
Growth Hormone-induced Diacylglycerol and Ceramide Formation via
G i3 and G in GH4 Pituitary Cells
POTENTIATION BY DOPAMINE-D2 RECEPTOR ACTIVATION*
Gele
Liu,
Liliane
Robillard,
Behzad
Banihashemi, and
Paul R.
Albert
From the Ottawa Health Research Institute, Neuroscience 451 Smyth
Road, Room 2464, University of Ottawa, Ottawa, Canada K1H 8M5
Received for publication, March 4, 2002, and in revised form, October 3, 2002
 |
ABSTRACT |
Growth hormone (GH) secretion is regulated by
indirect negative feedback mechanisms. To address whether GH has direct
actions on pituitary cells, lipid signaling in
GH4ZR7 somatomammotroph cells was examined. GH
(EC50 = 5 nM) stimulated diacylglycerol (DAG) and ceramide formation in parallel by over 10-fold within 15 min
and persisting for >3 h. GH-induced DAG/ceramide formation was blocked
by pertussis toxin (PTX) implicating Gi/Go
proteins and was potentiated 1.5-fold by activation of
Gi/Go-coupled dopamine-D2S receptors, which had
no effect alone. Following PTX pretreatment, only PTX-resistant
G i3, not G o or G i2,
rescued GH-induced DAG/ceramide signaling. GH-induced DAG/ceramide
formation was also blocked in cells expressing G blocker GRK-ct.
In GH4ZR7 cells, GH induced phosphorylation of
JAK2 and STAT5, which was blocked by PTX and mimicked by ceramide
analogue C2-ceramide or sphingomyelinase treatment to increase
endogenous ceramide. We conclude that in GH4 pituitary
cells, GH induces formation of DAG/ceramide via a novel
G i3/G -dependent pathway. This novel
pathway suggests a mechanism for autocrine feedback regulation by GH of
pituitary function.
 |
INTRODUCTION |
Pituitary somatotrophs synthesize and secrete
GH,1 which acts at the liver
and other tissues to stimulate IGF formation, promoting somatic growth
throughout the body (1, 2). Secretion of GH is stimulated by
hypothalamic GH-releasing hormone and inhibited by the hypothalamic
tetradecapeptide somatostatin and by IGF. In addition, somatostatin
agonists (e.g. octreotide) and dopamine-D2 agonists
(e.g. bromocryptine) are used clinically to treat acromegaly (a syndrome produced by hypersecretion of GH) and to inhibit
somatomammotroph growth and GH production (3). Negative feedback via
autocrine actions of GH at the pituitary has been postulated (4) but is
yet to be clearly demonstrated.
The GH receptor is a member of the type I cytokine receptor
superfamily, related to PRL and erythropoietin receptors that homodimerize to initiate signaling (5). The GH receptor signals through
the JAK2 tyrosine kinase-signal transducer and activator of
transcription 5 (STAT5) transcription factor pathway to induce gene
expression (6-9). Phosphorylation on residue Tyr-694 by JAK2 is
obligatory for STAT5 activation (10). The two STAT5 variants, STAT5a
and STAT5b, have 90% identical protein sequences and are independently
regulated and activated in various cell types (11). Studies using
STAT5a or STAT5b knockout mice have demonstrated that STAT5b, but not
STAT5a, is required for GH-induced regulation of IGF1 and sex-specific
steroidogenic enzymes in liver (11-13). While STAT5 activation is
implicated in many GH actions, other signaling pathways not involving
STAT5 appear to be recruited for GH-induced stimulation of other
pathways including MAPK phosphorylation and phosphatidyl inositol
3'-kinase or protein kinase C activation (14, 15) in a cell
type-dependent manner (16).
Ceramide is a novel second messenger implicated in regulation of cell
differentiation, proliferation, inflammation, and apoptosis (17-19).
Ceramide plays an important role in signaling of a subgroup of cytokine
receptors that includes tumor necrosis factor and interleukin-1
receptors (5, 15, 20, 21). However, the coupling of the GH/PRL-related
family of receptors to ceramide has not been reported. We therefore
examined whether GH might influence ceramide formation in pituitary
cells as part of an autocrine feedback pathway and whether dopamine-D2
agonists would influence GH action.
Rat pituitary tumor GH4C1 cells synthesize and secrete PRL and GH and
provide an excellent model of pituitary somatomammotrophs used for over
30 years (22). In this report we have identified a novel induction of
DAG and ceramide formation by GH that is blocked by PTX, implicating
the involvement of Gi/Go proteins (23). The
contribution of specific G subunits to GH autocrine signaling
pathways was addressed using PTX-insensitive mutants of
G i2, G i3, and G o
individually transfected into GH4ZR7 pituitary cells (GH4C1 cells transfected with the
dopamine-D2S receptor (24, 25)). In PTX-insensitive G protein mutants,
the carboxyl-terminal ribosyl-acceptor cysteine was changed to a
nonacceptor serine. The Cys-to-Ser mutation is a structurally
conservative change, and the mutant G proteins remain functional
following PTX pretreatment (26-28). The role of G subunits was
evaluated by using the carboxyl-terminal domain of G protein-coupled
receptor kinase (GRK-ct), a selective G scavenger (29). In
GH4ZR7 cells, dopamine-D2S receptor activation potentiated GH-induced DAG and ceramide formation. We have identified G i3 and G as crucial for both GH-induced ceramide
formation and dopamine-D2-induced potentiation of the GH response.
 |
MATERIALS AND METHODS |
Materials--
Apomorphine, dopamine, Staphylococcus
aureus SMase, PTX, 1,2-dioleoyl-rac-glycerol (C18:1[cis]-9),
DAG, puromycin, and all other drugs, standards, and salts were
purchased from Sigma. Human GH (iodination grade) and Escherichia
coli DAG kinase (13 units/mg protein) were from Calbiochem (San
Diego, CA). Sera, media, and Geneticin (G418) were obtained from
Invitrogen, Inc. [ -32P]ATP and
[ -32P]dCTP (>3000 Ci/mmol) were from Amersham
Biosciences. Thin-layer chromatography (TLC) plates (0.25 mm thick)
were purchased from Whatman. Solvents were supplied by BDH. Plasmids
pY3 and pCMV-LacZ II were obtained from the American Type Culture
Collection (Manassas, VA). The cDNAs encoding wild-type rat
G o, G i1, G i2, and
G i3 were generously provided by Dr. Randall Reed, Johns
Hopkins University, Baltimore, MD. Phospho-STAT5 (Tyr-694) antibody,
phosphoplus® STAT3 (Tyr-705) and phosphoplus® p44/42 MAPK antibody
kits were purchased from New England Biolabs (Mississauga, Ontario, Canada).
Plasmid Construction--
As previously described (27),
PTX-insensitive G i/o mutants were generated by point
mutation of rat cDNAs (30) encoding G i2 and
G i3 subunits at cysteine 351 (352 for
G i2). The TGT (cysteine codon) was mutated to TCT
(serine) and confirmed by Sanger dideoxynucleotide sequencing. The
mutant G i2 and G i3 cDNAs were
FLAG-tagged at the initiator ATG codon, and the cDNAs were
subcloned in KpnI-EcoRI-cut pcDNA3
(Invitrogen) to generate G i2-PTX,
G i3-PTX, and G o-PTX. The
carboxyl-terminal domain of OK-GRK2 cDNA (31), beginning from
Thr-493, was tagged at the amino-terminal with RGS-His6,
and the His-GRK-ct fragment was cloned into pcDNA3 to produce the
GRK-ct construct.
Cell Culture and
Transfection--
GH4ZR7 cells and derivative
clones were maintained in Ham's F10 medium with 8% fetal bovine serum
(FBS) at 37 °C, 5% CO2. G i2-PTX,
G i3-PTX, and G o-PTX (20 µg) were
cotransfected individually with pGK-puro (2 µg) into GH4ZR7 cells
using calcium phosphate co-precipitation. The transfected cells were
cultured in F10 + 8% FBS containing puromycin (20 µg/ml) for 3-4
weeks. Antibiotic-resistant clones were picked (24 clones/transfection)
and tested for expression of the corresponding G i/o
proteins by Western blot analysis. The following
G i2-PTX, G i3-PTX, G o-PTX
and GRK-ct clones were selected for analysis, respectively:
Gi2Z 24, Gi3Z 15, G o 15, and
GRKZ 17. These cells express about 2- to 3-fold times the endogenous
level of total G protein in GH4ZR7 cells,
suggesting that the ratio of PTX-insensitive/endogenous G proteins
in the clones was 1-2-fold (25).
Lipid Extraction--
Equivalent numbers of cells were cultured
in ten 10-cm plates with Ham's F10 medium plus 8% FBS in a humidified
atmosphere of 5% CO2, 95% air at 37 °C, grown to
80-90% confluence, and placed in serum-free F10 medium for 16 h.
For PTX treatment, the cells were treated with 10 ng/ml PTX for 16 h prior to experimentation. Cells were rinsed with serum-free F10
medium and treated with experimental compounds at 37 °C as
indicated. Following incubations, cells were twice rinsed with ice-cold
PBS and lipids extracted (32). After centrifugation at 500 × g for 1 min at 4 °C, the supernatants were aspirated and
the cells were lyzed with 0.5 ml of chloroform/methanol/HCl (20:40:1,
v/v/v), and sonicated in 5-s intervals × 6 on ice. Cells
were rinsed with 1 ml of chloroform and 0.3 ml of 1 M NaCl
and spun at 14,000 × g for 15 min at 4 °C. The
upper aqueous layer was discarded, and the lower lipid-containing layer
was transferred to a 1-ml glass Chrompack vial, dried under a stream of
O2-free N2 gas, and redissolved in 200 µl of
chloroform. The samples were stored at 80 °C until analysis. The
particulate protein interface was air-dried, dissolved in 0.5 ml of 2 M NaOH, and assayed for protein according to Lowry's method.
Quantification of DAG and Ceramide--
DAG and ceramide were
quantified using the DAG kinase method (33, 34). A blank tube and a
standard ceramide/DAG tube were included as controls. For each sample,
10 µl of DAG kinase (20 milliunits), 50 µl of reaction buffer (100 mM imidazole, pH 6.6, 25 mM MgCl2
and 2 mM EGTA), 10 µl of 20 mM
dithiothreitol, and 10 µl of [ -32P]ATP (2.5 × 105 dpm/nmol) were added and incubated at 25 °C for 30 min, and the reactions terminated by addition of 0.5-ml ice-cold
chloroform/methanol (1:2 v/v). The lipids were separated and extracted
by addition of 0.5 ml of chloroform and 0.5 ml of 1 M NaCl
spun at 14,000 × g for 3 min, and the upper aqueous
phase was discarded. The organic phase was sequentially washed with 0.5 ml of 1% perchloric acid, 0.3 ml of chloroform/methanol (1:2 v/v), 0.2 ml of chloroform, and 0.2 ml of water, dried under N2, and
reconstituted in 25 µl of chloroform/methanol (95:5, v/v). The
samples were spotted onto a Silica Gel 60 TLC plate, heat-activated,
and developed in a solvent mixture of
chloroform/acetone/methanol/acetic acid/water (10:4:3:2:1, v/v/v/v/v).
Since DAG kinase can use ceramide or DAG as substrate,
[32P]ceramide-phosphate represented ceramide production
and [32P]phosphatidic acid represented DAG production.
The TLC plates were exposed to phosphor screens for 18 h, and
[32P]ceramide-phosphate and
[32P]phosphatidic acid were quantified using the
Molecular Dynamics System ImageQuaNT computer software. Results are
expressed as percentage of control.
GH Binding Assay--
The binding assay was performed
using 50 µg of protein and 15,000 cpm/sample of
125I-hGH (2150 Ci/mmol, PerkinElmer Life Sciences) in a
final volume of 300 µl (0.021 nM final concentration) of
TME buffer (75 mM Tris, pH 7.4, 12.5 mM
MgCl2, 1 mM EDTA) containing 0.1% BSA (35). To
assess nonspecific binding 1 nM unlabeled hGH was added to the reaction. Incubation at room temperature was stopped after 30 min
by the addition of 500 µl of cold 100 mM Tris, pH 7.4. The reaction was then filtered through GF/C filters and washed three
times with 5 ml of cold 100 mM Tris, pH 7.4. Triplicate measurements were performed for all samples.
Western Blot Analysis--
Cells were treated as described
above. Cell pellets were frozen on dry ice/ethanol and stored at
-80 °C. Samples were sonicated 10-15 s, heated at 95 °C for 5 min, and centrifuged, and 40 µl/sample loaded onto SDS-PAGE gel and
electrotransferred to polyvinylidene difluoride membrane. The membrane
was blocked (1 h, room temperature), probed with primary antibody
(1:1000, overnight, 4 °C), washed in TBST (10 mM
Tris-HCl, pH 8, 150 mM NaCl, and 0.05% Tween 20) and incubated with horseradish peroxidase-conjugated secondary antibody
(1:2000) and horseradish peroxidase-conjugated anti-biotin antibody
(1:1000) to detect biotinylated protein markers (2 h at room
temperature). The blot was then washed, incubated with LumiGLO (1 min),
and exposed to x-ray film. Exposures in the linear range (gray scale)
were scanned and quantified using the UnScanIt program (Silk Scientific
Inc., Orem, Utah).
Statistical Analysis--
The data were analyzed by repeated
measure using analysis of variance for each set of experiments.
Differences of p < 0.05 were considered statistically significant.
 |
RESULTS |
Concentration- and Time-dependent Increase in
DAG/Ceramide Formation Induced by GH--
The acute action of GH on
endogenous DAG and ceramide levels in GH4ZR7
pituitary cells was assessed by the DAG kinase assay. The cells were
washed to remove extracellular (secreted) GH and assayed in serum-free
medium. GH induced a 10-fold increase in both DAG and ceramide
production in a concentration-dependent manner from
10 10 to 10 6 M at 20 min with an
EC50 of ~5 nM (Fig.
1). Addition of exogenous SMase (0.1 units/ml) was included as a positive control to demonstrate the
hydrolysis of endogenous SM to form ceramide. The phosphorylated DAG
and ceramide species co-migrated with the respective standards, confirming the identity of the products. GH (10 7
M) robustly increased both DAG and ceramide production in
parallel, which was maximal within 15 min and declined but remained
significantly elevated at 3 h (Fig.
2). Low levels of GH are secreted by
GH4C1 cells at a rate of 0.2 ng/ml/min or
10 11 mol/liter/min (36), sufficient to reach a
threshold concentration (10 9 M) for
DAG/ceramide formation in 1.5 h following initiation of treatments
(see "Materials and Methods"). However, GH is also metabolized,
hence the actual GH concentration under culture conditions may be lower
and did not appear to interfere with actions of exogenous GH.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 1.
Concentration-dependent
GH-induced DAG and ceramide formation in
GH4ZR7 cells. GH4ZR7
cells were treated with 10 10 to 10 6
M GH for 20 min. Lipids were extracted from cells, and
[32P]phosphatidic acid and
[32P]ceramide-phosphate were separated from other
32P-containing lipids by TLC to assay DAG and ceramide
content, respectively. A representative image of
[32P]phosphatidic acid and
[32P]ceramide-phosphate is shown above.
Below, the data are expressed as mean ± S.E. from
three independent experiments. *, p < 0.05; **,
p < 0.03; and ***, p < 0.01. B, blank; C, control; Std,
standard.
|
|

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
Sustained GH-induced increases in DAG and
ceramide production in GH4ZR7
cells. GH4ZR7 cells treated with
10 7 M GH for 15 min and 3 h. Lipids were
extracted from cells and separated as described under "Material and
Methods", and a representative image is shown. Below, the
quantified data from three independent experiments are expressed as
mean ± S.E. *, p < 0.03, and **,
p < 0.01. B, blank; C, control;
Std, standard.
|
|
PTX Blocks GH-induced Ceramide Production in
GH4ZR7 Cells--
We recently showed that in
Balb/c-3T3 fibroblasts, activation of the D2S receptor induces DAG and
ceramide formation that is blocked by PTX, which inactivates
Gi/Go
proteins.2 Cells were
pretreated with or without 10 ng/ml PTX for 16 h, a concentration
that blocks Gi/Go-mediated signaling in these cells (22). PTX treatment blocked GH-induced DAG and ceramide formation, thus implicating Gi/Go proteins
(Fig. 3). By contrast, PTX or dopamine-D2
agonist apomorphine (10 6 M) alone did not
alter DAG or ceramide formation. Importantly, PTX treatment did not
change the level of specific 125I-GH binding sites measured
in crude membranes from GH4ZR7 cells. Specific 125I-GH
binding was 118 ± 45 fmol/mg in GH4ZR7
cells (mean ± S.E., n = 3), and binding in
PTX-treated cells was 104 ± 8% of control binding, indicating
that blockade of GH-induced ceramide by PTX was not due to loss of
receptor sites.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 3.
GH, but not apomorphine, induces
PTX-sensitive DAG and ceramide production.
GH4ZR7 cells were treated with
10 7 M GH or 10 6 M
apomorphine with or without PTX pretreatment or treated with SMase 0.1 unit/ml, and a representative image of labeled DAG and ceramide
products of the DAG kinase assay is shown. Below, the data
are expressed as mean ± S.E. from three independent experiments.
*, p < 0.03. A, apomorphine; B,
blank; C, control; G, GH; P, PTX;
S, SMase, or combinations as indicated.
|
|
Apomorphine Potentiates GH-induced DAG and Ceramide Production in
GH4ZR7 Cells--
To examine further whether
activation of the D2S receptor modulates DAG or ceramide formation,
GH4ZR7 cells were incubated with GH,
apomorphine (a D2 receptor agonist) or both GH and apomorphine (Fig.
4). Although dopamine-D2S receptor
activation alone did not influence DAG or ceramide formation,
apomorphine potentiated by 1.5- to 2-fold times the GH-induced
formation of DAG and ceramide. In parental
GH4C1 cells, which lack dopamine receptors, GH
induced both DAG and ceramide formation but this effect was not
enhanced by apomorphine (data not shown), indicating that
apomorphine-induced potentiation is mediated via activation of
dopamine-D2S receptors present on GH4ZR7 cells.
Pretreatment with PTX blocked GH-induced ceramide production in
GH4ZR7 and GH4C1 cells
and also completely blocked DAG/ceramide production by apomorphine/GH
(Fig. 5), indicating that D2S-induced
potentiation of GH action involves Gi/Go
proteins.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 4.
Potentiation of GH-induced DAG and ceramide
formation by dopamine-D2 receptor activation.
GH4ZR7 cells were treated with
10 7 M GH, 10 6 M
apomorphine, both, or 0.1 unit/ml SMase for 20 min. Above, a
representative image of [32P]phosphatidic acid and
[32P]ceramide-phosphate is shown. Below, the
data are expressed as mean ± S.E. from three independent
experiments. *, p < 0.05; **, p < 0.03; and ***, p < 0.01. A, apomorphine;
B, blank; C, control; G, GH;
S, sphingomyelinase; Std, standard; or
combinations as indicated.
|
|

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 5.
Both GH- and apomorphine/GH-induced DAG and
ceramide formation is blocked by PTX pretreatment.
GH4ZR7 cells were treated as described in
previous figures, and representative image of labeled DAG and ceramide
products is shown above, and below averages of three experiments
(mean ± S.E.), *, p < 0.03 and **,
p < 0.01, compared with control. A: apomorphine; B:
blank; C: control; G: GH; P: PTX; S: sphingomyelinase; Std: standard;
or as indicated.
|
|
Rescue of GH-induced DAG and Ceramide Production by PTX-insensitive
G i3, but Not G i2 or G o and
Involvement of G Subunits--
We examined which subunit(s) of G
proteins mediate DAG or ceramide signaling induced by GH or
apomorphine/GH in combination using GH4ZR7
cells stably transfected with PTX-insensitive G mutants
(G i2-PTX and G i3-PTX cells) (25). As
observed in wild-type GH4ZR7 cells and in G i2-PTX and
G i3-PTX clones, the level of ceramide production induced
by combination of apomorphine and GH was greater than for GH alone
(Fig. 6 and data not shown). To examine
the importance of G i2-PTX and G i3-PTX,
cells were pretreated with PTX to block endogenous Gi/o
proteins and challenged with GH or apomorphine/GH in combination. PTX
blocked completely DAG and ceramide production stimulated by GH or
apomorphine/GH in G i2-PTX cells (Fig. 6). However in
G i3-PTX cells, both DAG and ceramide production were at
least 50% resistant to PTX pretreatment (Fig.
7). Since ~50% of the total
G i3 was PTX-sensitive endogenous protein (25), a
recovery of 50% of the response would be expected from the remaining
fraction of PTX-insensitive Gi3 proteins. Thus G i3, but not G i2, plays a crucial role in
both GH- and apomorphine/GH-induced DAG and ceramide formation. To
examine the role of G o subunits in GH-induced lipid
signaling, GH4ZR7 cells were stably transfected with
G o-PTX. In these cells, PTX completely blocked DAG and
ceramide formation induced by the combination of apomorphine and GH
(Fig. 8), indicating that like
G i2-PTX, G o-PTX does not rescue
GH-induced lipid signaling.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 6.
GH- or apomorphine/GH-induced DAG and
ceramide formation is not rescued by
G i2-PTX.
GH4ZR7 cells expressing PTX-insensitive G i2 were treated
as indicated in previous figures. Above is a representative
image of DAG and ceramide product. Below, data are expressed
as mean ± S.E. of three independent experiments. *,
p < 0.05; **, p < 0.03.
|
|

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 7.
Apomorphine/GH-induced DAG and ceramide
formation is rescued by
G i3-PTX. GH4ZR7 cells
expressing PTX-insensitive G i3 cDNA were treated for
20 min with 10 6 M apomorphine or apomorphine
and 10 7 M GH without or with PTX pretreatment
(10 ng/ml, 16 h). Abbreviations are as in previous figures.
Above is a representative image of labeled DAG and ceramide
products, and below averaged data are expressed as mean ± S.E. *, p < 0.03 and **, p < 0.01.
|
|

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 8.
G o-PTX
subunit fails to rescue DAG and ceramide signaling induced by
combination of apomorphine and GH. GH4ZR7
cells expressing PTX-insensitive G o were treated for 20 min with 10 6 M apomorphine or apomorphine and
10 7 M GH, without or with PTX pretreatment
(10 ng/ml, 16 h). A representative image of labeled DAG and
ceramide products is shown. Abbreviations are as in previous
figures.
|
|
As a selective G scavenger (29), the carboxyl-terminal domain of
G protein-coupled receptor kinase (GRK-ct) was used to examine the role
of G subunits in signaling to ceramide formation. We have
transfected GRK-ct into GH4ZR7 cells and
identified expression of GRK-ct by Western blot (25). Neither
apomorphine nor apomorphine/GH induced DAG or ceramide formation in
GRK-ct cells (Fig. 9). This suggests that
G subunits are necessary for ceramide formation induced by the
combination of apomorphine and GH.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 9.
GRK-ct blocks apomorphine/GH-induced DAG and
ceramide formation. GH4ZR7 cells
expressing the G scavenger GRK-ct were treated for 20 min with
10 6 M apomorphine or apomorphine and
10 7 M GH, without or with PTX pretreatment
(10 ng/ml, 16 h). A representative image of
[32P]phosphatidic acid and
[32P]ceramide-phosphate is shown. A,
apomorphine; A+G, apomorphine + GH; B, blank;
C, control; Std, standard.
|
|
GH and Ceramide Enhance JAK2/STAT5 Phosphorylation in
GH4ZR7 Cells--
Based on the results above,
we examined the influence of GH, apomorphine, PTX, and ceramide on well
known and potential downstream pathways of the GH receptor including
phosphorylation of JAK2, STAT5 (Fig.
10), STAT3 or MAPK. In
GH4ZR7 cells, GH alone increased phosphorylation of JAK2 (100% increase over basal) and STAT5 (40% increase), which was more strongly enhanced with both apomorphine and
GH (160% increase over basal for phospho-JAK2, 90% increase for
phospho-STAT5). Treatment with a ceramide analogue (C2-ceramide) or
SMase (to increase endogenous ceramide) also increased JAK2 phosphorylation by 90 and 150%, and STAT5 phosphorylation by 60 and
90%, respectively. Interestingly, PTX-blocked apomorphine/GH-induced STAT5 phosphorylation by 50%, further supporting a role for the PTX-sensitive ceramide pathway in GH-induced STAT5 phosphorylation in
these cells. By contrast, these compounds elicited no changes in STAT3
or MAPK phosphorylation (data not shown).

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 10.
PTX-sensitive regulation of JAK2/STAT5 by
GH, apomorphine/GH, and C2-ceramide.
GH4ZR7 cells were treated without
(control, C) or with GH (10 7 M,
G), apomorphine (10 6 M,
A), both (A+G), C2-ceramide (5 µM,
C2), or SMase (0.1 units/ml, S) for 30 min.
Pretreatment with 10 ng/ml of PTX (P) was for 16 h.
After harvesting cells, Western immunoblotting using antibodies to the
indicated phospho-protein or -actin (loading control) was carried
out. A, representative blots probed for phospho-JAK2
(p-JAK2), phospho-STAT5 (p-STAT5) and -actin as indicated.
B and C, data from three independent experiments
probed for phospho-JAK2 (B) or phospho-STAT5 (C)
were quantified using the Un-Scan-It program and are presented as
percent of control (mean ± S.E.); *, p < 0.03 and **, p < 0.01 compared with control.
|
|
 |
DISCUSSION |
GH-induced Coupling to G Proteins and Lipid Signaling--
Our
results indicate that GH induces a G protein-dependent
increase in lipid metabolism to generate DAG and ceramide in
GH4 cells. Previous studies in pre-adipocyte Ob1771 cells
(37, 38) and in pancreatic -cells (39) have shown that GH induces
DAG formation via activation of PC-PLC. By analogy, GH may activate PLC
in GH4 cells to induce DAG formation. Both DAG and ceramide formation were induced in parallel, suggesting interconversion between
these lipids possibly via SM synthase, which can convert DAG into
ceramide, leading to depletion of SM (40, 41). Alternately, DAG can
activate acidic SMase to generate ceramide (42, 43). Interconversion of
DAG to ceramide would account for the identical G i3 and
G dependencies of GH-mediated lipid formation.
The actions of GH in GH4 cells were sensitive to PTX
pretreatment, indicating a role for Gi/Go
proteins. Upon activation, GH receptors dimerize, associate with JAK2,
and recruit a family of negative regulators, the SOCS (suppressors of
cytokine signaling) proteins (44, 45). Coupling of the GH receptor to
PTX-sensitive G proteins is relatively unexplored, and potential
interactions of GH receptors or associated proteins such as SOCS
proteins with G proteins remain elusive. There is some evidence that
GH-like receptors interact with G proteins. In Nb2 cells,
G i proteins labeled by PTX-mediated ADP
ribosylation were cross-linked to the PRL receptor using a 16-Å
cross-linking agent, but not cross-linkers with shorter molecular
lengths, consistent with a direct physical interaction (46). In
addition, some PTX-sensitive GH-induced responses have been reported.
For example, GH-induced PC-PLC activation in Ob1771 preadipocytes (37,
38) and GH-mediated DAG formation and mitogenesis in pancreatic
-cells (39) are PTX-sensitive actions. Similarly, activation of the
homologous PRL receptor in Nb2 lymphoma cells enhances PTX labeling of
Gi proteins (suggesting activation) and induces
PTX-sensitive mitogenesis (47-49). Taken together, these results are
consistent with coupling of the GH receptor to PTX-sensitive
Gi proteins to activate PLC thereby generating DAG, which
can be converted to ceramide.
Although coupled to Gi/Go proteins, GH signaled
differently from the Gi/Go-coupled dopamine D2
receptor to induce PTX-sensitive DAG and ceramide formation since
apomorphine alone had no effect. Nevertheless there was an interaction
between GH and D2 signaling since apomorphine potentiated GH-induced
lipid signaling and JAK2/STAT5 activation. Furthermore, GH- and
apomorphine/GH-induced DAG and ceramide formation were both
rescued by G i3-PTX and blocked by GRK-ct, suggesting a
crucial role for G i3/G for both receptors. The
dopamine-D2 receptor utilizes Gi3 to mediate activation of potassium channels in pituitary cells (50) via binding of G to
the GIRK potassium channel (51), and is likely to couple to
G i3/G in GH4 pituitary cells. The mechanism by
which GH receptors couple to Gi3 remains to be elucidated,
but GH receptors appear to interact with Gi proteins
differently from Gi-coupled heptahelical receptors (such as
adenosine or D2S receptors). In adipocytes, GH prevented coupling of
adenosine receptor-mediated inhibition of cAMP and activation of
phosphatidylinositol-specific-PLC and blocked PTX-induced
ADP-ribosylation (52, 53). GH may induce relocalization of
G i subunits, prevent their coupling to adenylyl cyclase
(53, 54), and allow efficient coupling to DAG/ceramide formation. Since
sites of ceramide synthesis display discrete subcellular localization
(55), differences in the localization of D2S- and GH-receptor coupling
might account for their differing effectiveness to induce ceramide
formation in GH4 pituitary cells.
A Novel Pathway for GH-induced JAK2/STAT5 Activation--
Our data
show that C2-ceramide and sphingomyelinase induce JAK2/STAT5 activation
in GH4 cells, suggesting a link between GH-induced changes in
DAG/ceramide and the classical GH-receptor-mediated JAK/STAT pathway.
Consistent with our results, sphingomyelinase was shown to increase
ceramide levels and was found to activate JAK2 and STAT1/3 in cultured
human fibroblasts (56). Importantly, as observed for GH-mediated
ceramide formation, GH-induced JAK2/STAT5 activation was enhanced by
apomorphine and was partially blocked by PTX, suggesting that both G
protein-dependent and -independent pathways lead to
JAK2/STAT5 activation in these cells. Thus Gi-mediated ceramide signaling regulates GH-induced JAK2/STAT5 activation.
In addition to regulating JAK2/STAT5, GH-induced ceramide formation may
activate other signaling cascades (19). Both GH (16, 57) and ceramide
(19, 20) have been shown to activate the MAPK cascade in other cell
types, but we observed no induction of p42/44-MAPK by either GH or
ceramide in GH4 cells. Ceramide regulates other pathways including the
SAPK/JNK cascade, and several proapoptotic pathways, but the roles of
these pathways in GH4 cells is not known.
GH-mediated Autocrine Regulation of Pituitary Cells--
Multiple
negative feedback pathways regulate GH secretion at the level of the
hypothalamus and pituitary. At the level of the hypothalamus, GH
inhibits GH-releasing hormone synthesis and enhances somatostatin
release, resulting in decreased GH secretion at the pituitary (58-60).
GH-induced IGF formation is believed to be the primary negative
feedback pathway to inhibit GH synthesis in somatotrophs (1, 2). In
addition, Gi/Go-coupled dopamine-D2 and
somatostatin receptors also inhibit GH secretion and somatomammotroph growth (3). It is tempting to speculate that GH may negatively regulate
its own secretion; however, evidence for a non-IGF-mediated autocrine
pituitary feedback by GH is indirect (4, 61, 62). The GH receptor is
expressed in rat and human anterior pituitary and binds and
internalizes radiolabeled GH, suggesting a role for GH to regulate its
secretion from the pituitary (63-66). However, the signaling of the GH
receptor in pituitary cells has not been investigated. Our finding of a
novel G protein-mediated action of GH to induce DAG/ceramide as well as
JAK2/STAT5 activation in GH4 cells suggests a role for GH in regulation
of pituitary function. GH4 cells are a pituitary cell strain that has
provided an important model of somatotrophs that synthesize and secrete levels of GH that are sufficient to mediate autocrine GH-induced actions (22). Interestingly, C2-ceramide has been shown to inhibit GH
secretion from rat anterior pituitary cells (67), suggesting that
GH-induced ceramide formation could mediate negative feedback inhibition of GH secretion. Previously unexplored direct actions of GH
on DAG and ceramide may provide a more sensitive method to address
direct actions of GH in regulation of somatotroph function in
vivo.
 |
FOOTNOTES |
*
This work was supported by The National Cancer
Institute of Canada.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Holds the Novartis/Canadian Institutes for Health Research (CIHR)
Michael Smith Chair in Neurosciences. To whom correspondence should be
addressed. Tel.: 613-562-5800, ext.: 8307; Fax: 613-562-5403; E-mail:
palbert@uottawa.ca.
Published, JBC Papers in Press, October 9, 2002, DOI 10.1074/jbc.M202130200
2
Liu, G., Robillard, L., Banihashemi, B., and
Albert, P. R., in press.
 |
ABBREVIATIONS |
The abbreviations used are:
GH, growth hormone;
IGF, insulin-like growth factor;
DAG, diacylglycerol;
PRL, prolactin;
PTX, pertussis toxin;
JAK, Janus kinase;
STAT, signal transducing
activator of transcription;
SM, sphingomyelin;
TLC, thin-layer
chromatography;
FBS, fetal bovine serum;
PC-PLC, phosphatidyl choline
phospholipase C.
 |
REFERENCES |
| 1.
|
Melmed, S.,
Yamashita, S.,
Yamasaki, H.,
Fagin, J.,
Namba, H.,
Yamamoto, H.,
Weber, M.,
Morita, S.,
Webster, J.,
and Prager, D.
(1996)
Rec. Prog. Horm. Res.
51,
189-215[Medline]
[Order article via Infotrieve]
|
| 2.
|
Giustina, A.,
and Veldhuis, J. D.
(1998)
Endocr. Rev
19,
717-797[Abstract/Free Full Text]
|
| 3.
|
Colao, A.,
and Lombardi, G.
(1998)
Lancet
352,
1455-1461[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Asa, S. L.,
Coschigano, K. T.,
Bellush, L.,
Kopchick, J. J.,
and Ezzat, S.
(2000)
Am. J. Pathol.
156,
1009-1015[Abstract/Free Full Text]
|
| 5.
|
Gadina, M.,
Hilton, D.,
Johnston, J. A.,
Morinobu, A.,
Lighvani, A.,
Zhou, Y. J.,
Visconti, R.,
and O'Shea, J. J.
(2001)
Curr. Opin. Immunol.
13,
363-373[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Kelly, P. A.,
Goujon, L.,
Sotiropoulos, A.,
Dinerstein, H.,
Esposito, N.,
Edery, M.,
Finidori, J.,
and Postel-Vinay, M. C.
(1994)
Horm. Res.
42,
133-139[Medline]
[Order article via Infotrieve]
|
| 7.
|
Herrington, J.,
Smit, L. S.,
Schwartz, J.,
and Carter-Su, C.
(2000)
Oncogene
19,
2585-2597[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Zhu, T.,
Goh, E. L.,
Graichen, R.,
Ling, L.,
and Lobie, P. E.
(2001)
Cell. Signal.
13,
599-616[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Herrington, J.,
and Carter-Su, C.
(2001)
Trends Endocrinol. Metab.
12,
252-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Gouilleux, F.,
Wakao, H.,
Mundt, M.,
and Groner, B.
(1994)
EMBO J.
13,
4361-4369[Medline]
[Order article via Infotrieve]
|
| 11.
|
Park, S. H.,
Liu, X.,
Hennighausen, L.,
Davey, H. W.,
and Waxman, D. J.
(1999)
J. Biol. Chem.
274,
7421-7430[Abstract/Free Full Text]
|
| 12.
|
Davey, H. W.,
Xie, T.,
McLachlan, M. J.,
Wilkins, R. J.,
Waxman, D. J.,
and Grattan, D. R.
(2001)
Endocrinology
142,
3836-3841[Abstract/Free Full Text]
|
| 13.
|
Davey, H. W.,
Park, S. H.,
Grattan, D. R.,
McLachlan, M. J.,
and Waxman, D. J.
(1999)
J. Biol. Chem.
274,
35331-35336[Abstract/Free Full Text]
|
| 14.
|
Moutoussamy, S.,
Renaudie, F.,
Lago, F.,
Kelly, P. A.,
and Finidori, J.
(1998)
J. Biol. Chem.
273,
15906-15912[Abstract/Free Full Text]
|
| 15.
|
Moutoussamy, S.,
Kelly, P. A.,
and Finidori, J.
(1998)
Eur. J. Biochem.
255,
1-11[Medline]
[Order article via Infotrieve]
|
| 16.
|
Love, D. W.,
Whatmore, A. J.,
Clayton, P. E.,
and Silva, C. M.
(1998)
Endocrinology
139,
1965-1971[Abstract/Free Full Text]
|
| 17.
|
Liu, B.,
Obeid, L. M.,
and Hannun, Y. A.
(1997)
Semin. Cell Dev. Biol.
8,
311-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Basu, S.,
and Kolesnick, R.
(1998)
Oncogene
17,
3277-3285[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Liu, G.,
Kleine, L.,
and Hebert, R. L.
(1999)
Crit. Rev. Clin. Lab. Sci.
36,
511-573[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Raines, M. A.,
Kolesnick, R. N.,
and Golde, D. W.
(1993)
J. Biol. Chem.
268,
14572-14575[Abstract/Free Full Text]
|
| 21.
|
Waters, M. J.,
Shang, C. A.,
Behncken, S. N.,
Tam, S. P., Li, H.,
Shen, B.,
and Lobie, P. E.
(1999)
Clin. Exp. Pharmacol. Physiol.
26,
760-764[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Albert, P. R.
(1994)
Vitam. Horm.
48,
59-109[Medline]
[Order article via Infotrieve]
|
| 23.
|
Birnbaumer, L.
(1992)
Cell
71,
1069-1072[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Albert, P. R.,
Neve, K. A.,
Bunzow, J. R.,
and Civelli, O.
(1990)
J. Biol. Chem.
265,
2098-2104[Abstract/Free Full Text]
|
| 25.
|
Banihashemi, B.,
and Albert, P. R.
(2002)
Mol. Endocrinol.
16,
2393-2404[Abstract/Free Full Text]
|
| 26.
|
Chuprun, J. K.,
Raymond, J. R.,
and Blackshear, P. J.
(1997)
J. Biol. Chem.
272,
773-781[Abstract/Free Full Text]
|
| 27.
|
Ghahremani, M. H.,
Cheng, P.,
Lembo, P. M.,
and Albert, P. R.
(1999)
J. Biol. Chem.
274,
9238-9245[Abstract/Free Full Text]
|
| 28.
|
Ghahremani, M. H.,
Forget, C.,
and Albert, P. R.
(2000)
Mol. Cell. Biol.
20,
1497-1506[Abstract/Free Full Text]
|
| 29.
|
Koch, W. J.,
Hawes, B. E.,
Inglese, J.,
Luttrell, L. M.,
and Lefkowitz, R. J.
(1994)
J. Biol. Chem.
269,
6193-6197[Abstract/Free Full Text]
|
| 30.
|
Jones, D. T.,
and Reed, R. R.
(1987)
J. Biol. Chem.
262,
14241-14249[Abstract/Free Full Text]
|
| 31.
|
Lembo, P. M.,
Ghahremani, M. H.,
and Albert, P. R.
(1999)
Mol. Endocrinol.
13,
138-147[Abstract/Free Full Text]
|
| 32.
|
Bligh, E. G.,
and Dyer, W. J.
(1959)
Can. J. Biochem. Physiol.
37,
911-917[Medline]
[Order article via Infotrieve]
|
| 33.
|
Preiss, J.,
Loomis, C. R.,
Bishop, W. R.,
Stein, R.,
Niedel, J. E.,
and Bell, R. M.
(1986)
J. Biol. Chem.
261,
8597-8600[Abstract/Free Full Text]
|
| 34.
|
Wright, T. M.,
Rangan, L. A.,
Shin, H. S.,
and Raben, D. M.
(1988)
J. Biol. Chem.
263,
9374-9380[Abstract/Free Full Text]
|
| 35.
|
Klempt, M.,
Bingham, B.,
Breier, B. H.,
Baumbach, W. R.,
and Gluckman, P. D.
(1993)
Endocrinology
132,
1071-1077[Abstract/Free Full Text]
|
| 36.
|
Albert, P. R.,
and Tashjian, A. H., Jr.
(1984)
J. Biol. Chem.
259,
15350-15363[Abstract/Free Full Text]
|
| 37.
|
Doglio, A.,
Dani, C.,
Grimaldi, P.,
and Ailhaud, G.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1148-1152[Abstract/Free Full Text]
|
| 38.
|
Catalioto, R. M.,
Ailhaud, G.,
and Negrel, R.
(1990)
Biochem. Biophys. Res. Commun.
173,
840-848[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Sjoholm, A.,
Zhang, Q.,
Welsh, N.,
Hansson, A.,
Larsson, O.,
Tally, M.,
and Berggren, P. O.
(2000)
J. Biol. Chem.
275,
21033-21040[Abstract/Free Full Text]
|
| 40.
|
van Helvoort, A.,
van't Hof, W.,
Ritsema, T.,
Sandra, A.,
and van Meer, G.
(1994)
J. Biol. Chem.
269,
1763-1769[Abstract/Free Full Text]
|
| 41.
|
Luberto, C.,
and Hannun, Y. A.
(1998)
J. Biol. Chem.
273,
14550-14559[Abstract/Free Full Text]
|
| 42.
|
Schutze, S.,
Machleidt, T.,
and Kronke, M.
(1994)
J. Leukoc. Biol.
56,
533-541[Abstract]
|
| 43.
|
Schutze, S.,
Wiegmann, K.,
Machleidt, T.,
and Kronke, M.
(1995)
Immunobiology
193,
193-203[Medline]
[Order article via Infotrieve]
|
| 44.
|
Finidori, J.
(2000)
Vitam. Horm.
59,
71-97[Medline]
[Order article via Infotrieve]
|
| 45.
|
Ram, P. A.,
and Waxman, D. J.
(1999)
J. Biol. Chem.
274,
35553-35561[Abstract/Free Full Text]
|
| 46.
|
Too, C. K.,
Shiu, R. P.,
and Friesen, H. G.
(1990)
Biochem. Biophys. Res. Commun.
173,
48-52[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Larsen, J. L.,
and Dufau, M. L.
(1988)
Endocrinology
123,
438-444[Abstract/Free Full Text]
|
| 48.
|
Too, C. K.,
Murphy, P. R.,
and Friesen, H. G.
(1989)
Endocrinology
124,
2185-2192[Abstract/Free Full Text]
|
| 49.
|
Larsen, J. L.
(1992)
J. Biol. Chem.
267,
10583-10587[Abstract/Free Full Text]
|
| 50.
|
Lledo, P. M.,
Homburger, V.,
Bockaert, J.,
and Vincent, J. D.
(1992)
Neuron
8,
455-463[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Clapham, D. E.,
and Neer, E. J.
(1997)
Annu. Rev. Pharmacol. Toxicol.
37,
167-203[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Roupas, P.,
Chou, S. Y.,
Towns, R. J.,
and Kostyo, J. L.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1691-1695[Abstract/Free Full Text]
|
| 53.
|
Doris, R. A.,
Kilgour, E.,
Houslay, M. D.,
and Vernon, R. G.
(1998)
J. Endocrinol.
158,
295-303[Abstract]
|
| 54.
|
Yip, R. G.,
and Goodman, H. M.
(1999)
Endocrinology
140,
1219-1227[Abstract/Free Full Text]
|
| 55.
|
Hannun, Y. A.,
and Obeid, L. M.
(2002)
J. Biol. Chem.
277,
25847-25850[Free Full Text]
|
| 56.
|
Maziere, C.,
Conte, M. A.,
and Maziere, J. C.
(2001)
FEBS Lett.
507,
163-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Yarwood, S. J.,
Sale, E. M.,
Sale, G. J.,
Houslay, M. D.,
Kilgour, E.,
and Anderson, N. G.
(1999)
J. Biol. Chem.
274,
8662-8668[Abstract/Free Full Text]
|
| 58.
|
Peng, X. D.,
Park, S.,
Gadelha, M. R.,
Coschigano, K. T.,
Kopchick, J. J.,
Frohman, L. A.,
and Kineman, R. D.
(2001)
Endocrinology
142,
1117-1123[Abstract/Free Full Text]
|
| 59.
|
Kamegai, J.,
Unterman, T. G.,
Frohman, L. A.,
and Kineman, R. D.
(1998)
Endocrinology
139,
3554-3560[Abstract/Free Full Text]
|
| 60.
|
Zheng, H.,
Bailey, A.,
Jiang, M. H.,
Honda, K.,
Chen, H. Y.,
Trumbauer, M. E.,
Van der Ploeg, L. H.,
Schaeffer, J. M.,
Leng, G.,
and Smith, R. G.
(1997)
Mol. Endocrinol.
11,
1709-1717[Abstract/Free Full Text]
|
| 61.
|
Nakamoto, J. M.,
Gertner, J. M.,
Press, C. M.,
Hintz, R. L.,
Rosenfeld, R. G.,
and Genel, M.
(1986)
J. Clin. Endocrinol. Metab.
62,
822-826[Abstract/Free Full Text]
|
| 62.
|
Ross, R. J.,
Borges, F.,
Grossman, A.,
Smith, R.,
Ngahfoong, L.,
Rees, L. H.,
Savage, M. O.,
and Besser, G. M.
(1987)
Clin. Endocrinol.
26,
117-123[Medline]
[Order article via Infotrieve]
|
| 63.
|
Mertani, H. C.,
Pechoux, C.,
Garcia-Caballero, T.,
Waters, M. J.,
and Morel, G.
(1995)
J. Clin. Endocrinol. Metab.
80,
3361-3367[Abstract]
|
| 64.
|
Mertani, H. C.,
Waters, M. J.,
Jambou, R.,
Gossard, F.,
and Morel, G.
(1994)
Neuroendocrinology
59,
483-494[Medline]
[Order article via Infotrieve]
|
| 65.
|
Harvey, S.,
Baumbach, W. R.,
Sadeghi, H.,
and Sanders, E. J.
(1993)
Endocrinology
133,
1125-1130[Abstract/Free Full Text]
|
| 66.
|
Fraser, R. A.,
Siminoski, K.,
and Harvey, S.
(1991)
J. Endocrinol.
128,
R9-R11[Abstract/Free Full Text]
|
| 67.
|
Negishi, T.,
Chik, C. L.,
and Ho, A. K.
(1999)
Endocrinology
140,
5691-5697[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. C.P. Thirone, L. JeBailey, P. J. Bilan, and A. Klip
Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells: Possible Target to Ameliorate Insulin Resistance.
Diabetes,
April 1, 2006;
55(4):
942 - 951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. D. Khoa, M. Postow, J. Danielsson, and B. N. Cronstein
Tumor Necrosis Factor-{alpha} Prevents Desensitization of G{alpha}s-Coupled Receptors by Regulating GRK2 Association with the Plasma Membrane
Mol. Pharmacol.,
April 1, 2006;
69(4):
1311 - 1319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Wu, R. Tandon, J. Ziembicki, J. Nagano, K. M. Hujer, R. T. Miller, and C. Huang
Role of ceramide in Ca2+-sensing receptor-induced apoptosis
J. Lipid Res.,
July 1, 2005;
46(7):
1396 - 1404.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|